Loratyne

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loratyne

Property Description
Active ingredient Loratadine
Form Tablet, Syrup, Oral Solution, Chewable Tablet
Pharmacological class Second-generation H1-Antihistamine
General Purpose Relief from allergic reactions
Origin Synthetic Compound

What Type of Medicine is Loratyne?

Loratyne is a pharmaceutical entity containing the active compound Loratadine, which is classified as a synthetic, long-acting second-generation H1-antihistamine. Loratadine is chemically derived from the piperidine group, distinguishing it from older classes of allergy medication.

The medication's core identity is defined by its highly selective action as a peripheral H1-receptor antagonist. Pharmacological studies confirm that it exhibits minimal penetration of the blood-brain barrier. This is a vital differentiating factor, as it means Loratyne is fundamentally positioned as a non-sedating antihistamine, thereby offering symptomatic relief without the significant drowsiness associated with many first-generation compounds.

Composition and Forms of Loratyne

The essential component of Loratyne is the Loratadine active ingredient, which functions primarily as a single-ingredient product, although fixed combination formulations also exist. Loratyne is strictly intended for the oral route of administration, and the availability across multiple dosage form(s) provides key flexibility.

These forms include the standard tablet, liquid formats such as syrup and oral solution often preferred for pediatric use, and specialized forms like the chewable tablet. These preparations utilize the active substance combined with general carriers such as lactose and starch for solid dosage forms, or an aqueous solution base for liquid formats.

What is the General Purpose of Loratyne?

The primary objective of Loratyne is to deliver effective antiallergic action by stabilizing the body's internal response to environmental triggers. This is achieved via Histamine H1-receptor blocking, which prevents the body’s naturally released histamine from triggering an allergic response in peripheral tissues. By inhibiting this action, Loratyne effectively manages the discomfort caused by the excessive release of histamine in allergic situations, providing generalized relief from the body's overreaction.

Regulatory References

  1. MedlinePlus

What side effects are possible with Loratyne?

Possible Side Effects and Safety Information

The safety profile of Loratyne (Loratadine) is structured according to regulatory classifications detailing the frequency and type of adverse reactions observed during clinical trials and post-marketing surveillance. The primary documented side effects are categorized by frequency, helping to distinguish between common and less frequent occurrences.


Adverse Reaction Classifications

Adverse events are formally grouped by how frequently they are reported:

  • Common (may affect up to 1 in 10 people): Headache, Somnolence (Drowsiness), and Fatigue.
  • Uncommon (may affect up to 1 in 100 people): Insomnia and Increased Appetite.
  • Very Rare (may affect up to 1 in 10,000 people): Documented reactions include those affecting the Hepatobiliary Disorders (e.g., Jaundice, Abnormal Hepatic Function) and Cardiac Disorders (e.g., Palpitations, Tachycardia).

Serious adverse reactions, though very rare, include reports of Anaphylaxis (a severe hypersensitivity reaction) and significant Hepatic Dysfunction, as noted in regulatory documents. These events are classified within System-Organ Classes such as Immune System Disorders and Hepatobiliary Disorders.


Safety Considerations and Restrictions

Specific regulatory safety statements apply to certain populations and circumstances. The use of Loratyne is formally contraindicated in individuals with known hypersensitivity to the active substance or its excipients.

Patients with severe hepatic impairment represent a population with reduced drug clearance, necessitating consideration of a reduced frequency of administration as per prescribing information. Furthermore, co-administration with inhibitors of CYP3A4 or CYP2D6 may increase the plasma concentration of Loratadine, which is a documented safety consequence.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Loratyne (Loratadine) is associated with documented clinical signs, primarily involving the central nervous and cardiovascular systems. The most commonly reported manifestations in regulatory sources include somnolence (drowsiness), headache, and tachycardia (fast or pounding heartbeat). Higher-than-recommended doses can increase the risk of severe outcomes, such as convulsion (seizure) and potentially serious cardiac effects, including arrhythmias and prolongation of the QT-interval.


Emergency Actions and Required Medical Attention

When overdose is suspected, official regulatory guidance mandates that users must seek immediate medical attention or contact a Poison Control Center immediately. Urgent medical assistance is required if severe symptoms occur, particularly convulsion or if the person has collapsed or cannot be awakened.

No specific antidote is known for Loratadine overdose. Treatment relies entirely on the institution of general symptomatic and supportive measures. Procedures such as the administration of activated charcoal or gastric lavage may be considered, and medical monitoring of the patient must be continued after initial emergency measures. Special consideration applies to patients with severe liver impairment and the elderly, who may have an increased risk of toxicity. The compound is not removed by haemodialysis.

Therapeutic Uses of Loratyne

Quick Facts

  • Primary Use: Management of symptoms associated with seasonal and perennial allergic rhinitis.
  • Secondary Use: Temporary relief of symptoms of chronic idiopathic urticaria (hives).
  • Symptom Support: May help relieve sneezing, runny nose, and itching of the eyes, nose, or throat.

Loratyne is indicated for the symptomatic management of conditions resulting from allergic reactions. Its approved use includes addressing symptoms linked to seasonal allergic rhinitis, commonly known as hay fever. This encompasses the temporary relief of common issues such as sneezing, watery eyes, and a runny nose. The medication is also utilized to help manage perennial allergic rhinitis, which presents with symptoms year-round.

Additionally, Loratyne is a treatment option for the temporary relief of symptoms associated with chronic idiopathic urticaria, or hives. This may include helping to minimize associated itching and the appearance of the skin rash. The therapeutic goal is to address the discomfort caused by these allergic manifestations and support a reduction in symptomatic severity.

Eligibility and Restrictions for Use

Eligibility Scope

The official regulatory profile for Loratyne defines eligibility based on a patient’s age, known allergies, and specific underlying health conditions.

Eligibility Status Population/Condition
Contraindicated Known hypersensitivity to the active substance Loratadine, its metabolite Desloratadine, or any excipient.
Not Established Children under 2 years of age.
Not Recommended Pregnant or breastfeeding individuals.
Conditional Use Patients with severe hepatic (liver) or renal (kidney) impairment.

Age-Based Eligibility

Loratyne is permitted for use by Adults and Adolescents (12 years of age and older). For Children, eligibility begins at 2 years of age for liquid formulations and 6 years of age for standard tablets. Use is not established below the age of two.

Condition-Specific Limitations

Patients with severe liver or kidney dysfunction are subject to conditional use due to the potential for reduced drug clearance. Additionally, certain oral formulations are restricted for patients with specific metabolic disorders, such as Phenylketonuria, based on the presence of excipients.

Connection to the Overall Eligibility Profile

Regulatory documents establish the profile by setting absolute prohibitions for hypersensitivity and defining conditional use for populations with impaired organ function. All other individuals meeting the approved age and health criteria are considered eligible for use under standard labeled conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Loratyne (Loratadine) based primarily on its metabolic pathway and required administration constraints.

Pharmacokinetic Interactions

Loratyne is metabolized predominantly by the enzyme CYP3A4 and to a lesser extent by CYP2D6. Co-administration with medicines that inhibit these enzymes can interfere with Loratadine's clearance, leading to substantially increased plasma concentrations of Loratadine and its active metabolite. This pharmacokinetic interaction is documented with the following specific substances:

  • Ketoconazole
  • Erythromycin
  • Cimetidine

In studies, this increase in drug exposure was noted by the European regulatory body to occur without clinically significant changes. However, caution regarding increased exposure is required.

Other Interactions and Restrictions

Interaction Entity Official Regulatory Statement
Food (High-Fat Meal) Increases the systemic bioavailability (AUC) of Loratadine by approximately 40% to 48%.
Alcohol Loratadine exhibits no potentiating effects on psychomotor performance when co-administered with alcohol.
Skin Test Procedures Administration must be discontinued 48 hours prior to any scheduled cutaneous diagnostic skin test procedures.
Specific Populations Individuals with hepatic impairment, renal impairment, and the elderly may be more susceptible to the effects of increased exposure when co-administered with CYP-inhibiting medicines.

Mechanism of Action

Loratyne acts as a selective peripheral H1 receptor antagonist. This action involves competitive inhibition of the endogenous ligand, histamine, at the H1 receptor site in target tissues. By binding to the receptor, Loratyne blocks the ability of histamine to initiate its natural response.

The compound rapidly undergoes first-pass metabolism in the liver to form an active metabolite, X (descarboethoxyloratadine). This metabolite, which also exhibits high selectivity for the peripheral H1 receptor, is the primary contributor to the overall pharmacological mechanism.

Antagonism of the H1 receptor prevents the associated Gq-protein coupled receptor from activating its downstream signaling cascade. This molecular mechanism specifically blocks the histamine-mediated increase in intracellular Ca^2+ mobilization and the subsequent release of inflammatory mediators from mast cells and basophils.

Dosage and Administration Information

How to use Loratyne

The use of Loratyne (Loratadine) is governed by instructions that standardize its oral administration and once-daily dosing frequency. The medication is designated strictly for the oral route in all available forms, including the conventional tablet, syrup, and the orally disintegrating tablet.


Administration Scope

Instruction Entity Detail
Route of Administration Oral use only.
Dosing Schedule Adults/Children 6 years: 10 mg once daily. Children 2 to 5 years: 5 mg once daily.
Timing in relation to meals May be taken without regard to meals (with or without food).
Preparation Requirements Orally Disintegrating Tablets (ODT) are placed on the tongue to dissolve and may be swallowed with or without water. Chewable tablets must be crushed or chewed before swallowing.
Special Procedural Conditions Severe Liver Impairment: An initial dose of 10 mg every other day is recommended for adults and children over 30 kg.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily (q.d.)
Use-context constraints Strict 10 mg/24 hours maximum dose limit.

Resulting Procedural Structure

Step sequence:

  • The prescribed dose must be taken once daily, and the total amount should not exceed 10 mg in a 24 hour period.
  • The dose can be administered without concern for mealtimes.
  • When a dose is missed, it should be skipped if it is close to the time for the next scheduled dose; a double dose must not be taken.

Connection to the overall use protocol (2–4 sentences): The instructions establish a simplified, long-acting use protocol through a once-daily oral schedule that is fixed for most patient groups. This structure is intended to guide the appropriate frequency, dose quantity, and required physical preparation steps for the various oral forms, with the most critical adjustment being the reduction of the dosing interval for severe hepatic impairment.

Recent Clinical Evidence

Loratyne: Recent Clinical Evidence


Evidence for use in Seasonal Allergic Rhinitis (Hay Fever)

Research has explored Loratyne's use in conditions characterized by fluctuating or episodic manifestations, such as seasonal allergic rhinitis. Studies conducted for this indication were often randomized, controlled trials. These studies typically monitored patient-reported outcomes describing perceived discomfort related to classic seasonal allergy symptoms. The findings describe patterns observed in the studies where data show patterns related to symptom scores when compared to placebo. Research highlights changes measured during the study period, indicating that Loratyne studies monitored symptom scores compared to placebo. Results apply only to the populations studied, and follow-up durations were often limited, meaning that research provides context but not individual predictions.

Evidence for use in Chronic Idiopathic Urticaria (Hives)

Loratyne was studied for its application in chronic idiopathic urticaria (CIU), a condition involving periods of heightened symptoms characterized by hives and itching. The evidence in this area is mainly derived from clinical trials that examined outcomes related to physical discomfort and daily functioning. Studies explored the evaluation of Loratyne in managing outcomes linked to inflammatory states of the skin. Research describes findings that indicate Loratyne contributes to understanding symptom patterns by studies monitored symptom intensity or variability compared to placebo in the observed populations. Comparative evidence is lacking, and data for certain groups remain insufficient.


Long-term Studies and Follow-up

Research has examined Loratyne's use over defined time intervals. These studies explored what is known and unknown about the durability of response—meaning how changes in symptom patterns evolved during the study period with continued use. Long-term effects are not fully established beyond the time frame of these studies, and certainty remains low regarding outcomes after many months or years of continuous use. There is limited information for long-term outcomes, and research is ongoing.

Evidence in Special Populations and Uncertainties

Loratyne was evaluated in special populations, including children and older adults, to understand how outcomes related to functional imbalance might vary. Data for certain groups, such as those with underlying kidney or liver disease, are available, and these studies suggest that data show patterns related to findings in these groups. The overall research landscape still contains areas where data remain insufficient. Certainty remains low in several domains, and the existing evidence quality varies across studies, indicating a need for more definitive research.

Frequently Asked Questions (FAQ)

Common questions about Loratyne (FAQ)

Q: Does Loratyne cause weight gain?

A: Regulatory safety documents include 'weight increased' as a reported adverse reaction. This specific effect is classified as having a frequency that is 'not known,' meaning the exact rate of occurrence cannot be estimated from the available data. Official documents in some regions also list 'increased appetite' as an uncommon side effect.

Q: Are there any specific supplements or vitamins that should not be taken with Loratyne?

A: Official information regarding drug metabolism notes that Loratyne is broken down in the body by specific enzymes (CYP3A4 and CYP2D6). Co-administration with any substance, including supplements, that strongly blocks these enzymes may lead to increased levels of Loratyne in the bloodstream. It is important for patients to inform a healthcare provider about all supplements and vitamins being taken.

Q: Can Loratyne interact with herbal remedies like St. John's Wort?

A: Regulatory guidance advises caution, as some herbal remedies may potentially reduce the drug's effectiveness by influencing the body's natural breakdown process. This concern is related to how the remedies may affect the enzymes responsible for clearing Loratyne from the body.

Q: Does Loratyne affect my sleep quality?

A: Official reports on side effects indicate varying effects on sleep. Drowsiness (somnolence) is listed as a common side effect, especially in adults and older children. Conversely, difficulty sleeping (insomnia) is also noted as an uncommon side effect. The overall effect on sleep can differ among individuals.

Q: What is the difference between brand name Loratyne and the generic version?

A: According to regulatory standards, generic versions of the drug must contain the same active ingredient (Loratadine) as the brand-name product. Both versions are required to have the same strength, dosage form, and route of administration, and they are expected to work the same way in the body. Differences typically exist only in the price, the product's appearance, and the inactive ingredients used.

Q: Are there different formulas of Loratyne, like chewable or liquid?

A: Yes, official product information confirms that Loratyne is available in multiple forms suitable for oral use. These forms include standard tablets, syrup, oral solution, chewable tablets, and orally disintegrating tablets (ODT). These options provide flexibility for use across different age groups and needs.

Q: What happens if you take more Loratyne than recommended on the label?

A: Official reports on taking too much of the drug document an increased occurrence of side effects often referred to as anticholinergic symptoms. Effects reported in this context include somnolence, tachycardia (a fast heartbeat), and headache. Regulatory guidance recommends immediate medical evaluation or assistance if an overdosage is suspected.

Q: What is the main difference between Loratyne and other similar medications?

A: Loratyne is formally classified as a non-sedating second-generation H1-antihistamine. This classification is used to distinguish it from older, first-generation antihistamines, which are more widely associated with central nervous system effects like significant drowsiness and cognitive impairment.

Q: Why is Loratyne available without a prescription in some places?

A: Regulatory bodies make a medicine available over-the-counter (OTC) after determining it can be safely and effectively used by the public without the supervision of a healthcare provider. This decision is based on the drug's established safety profile, low potential for misuse, and simple administration instructions.

Q: How long does it typically take for Loratyne to start working?

A: Clinical studies and official product information indicate that the antihistaminic effect of a single oral dose typically begins to be observed within one to three hours after it is taken. The effects are generally seen to reach their maximum concentration between eight and twelve hours.

Q: How long does the effect of one dose of Loratyne last?

A: Official studies show that the antihistaminic effect has been demonstrated to last in excess of 24 hours. This prolonged duration is the basis for the regulatory recommendation that the medication be taken just once a day.

Q: Can Loratyne be taken with food, or does it need to be on an empty stomach?

A: Official administration instructions state that Loratyne may be taken without regard to meals, meaning it can be taken with or without food. Although food, especially high-fat meals, can slightly delay how quickly the drug is absorbed and increase the total amount of drug in the body, this difference is generally considered not to impact the medication's clinical effect.

Q: Is Loratyne safe to take every day for a long period?

A: Regulatory documents indicate that the drug is approved for chronic conditions and is generally tolerated well for longer periods than first-generation drugs. However, official safety summaries also state that the long-term effects are not fully established beyond the time frame covered in the clinical studies. The decision regarding extended use is typically made with consideration of individual circumstances.

Q: Can Loratyne affect my ability to drive or operate machinery?

A: Because official warnings note that Loratyne may cause drowsiness or dizziness in some individuals, regulatory warnings advise caution. Individuals should not perform tasks requiring full alertness until they are aware of the medication's effect on them.

Q: Does Loratyne help with hives or just seasonal allergies?

A: Official documents confirm that the drug is formally indicated for the relief of symptoms associated with both Seasonal Allergic Rhinitis (commonly known as hay fever) and Chronic Idiopathic Urticaria (commonly known as hives).

Q: Why are there different strengths of Loratyne available?

A: The availability of different strengths, such as 10 text mg and 5 text mg, is based on the need to accommodate the different recommended doses for various patient populations. Official dosing schedules are fixed according to age and body weight, necessitating the availability of multiple strengths.

Q: Have there been any major studies about the long-term safety of Loratyne?

A: Regulatory documents confirm that studies have explored the drug's use over defined time intervals to assess its safety profile. However, official safety summaries explicitly note that long-term effects are not fully established beyond the time frame of the clinical studies that have been conducted.

Q: Is Loratyne known to cause dry mouth?

A: Yes, dry mouth is a documented adverse reaction associated with this medication. Official post-marketing surveillance reports list it as a very rare side effect.

Q: Is there a specific time of day when Loratyne should be taken?

A: The official frequency pattern for Loratyne is to be taken once daily. While it can be taken at any time, some patients prefer to take it in the morning. Consistency in the once-daily schedule is the key regulatory instruction.

Q: Can Loratyne be crushed or mixed into food for easier swallowing?

A: The official requirements for taking the drug depend on the specific form: Chewable tablets must be chewed or crushed before swallowing. Orally disintegrating tablets (ODTs) are designed to dissolve on the tongue. Standard tablets are generally intended to be swallowed whole and are not typically instructed to be crushed.

Q: Is it normal for Loratyne to stop working after a while?

A: The phenomenon where a drug loses its effectiveness over time is known as tolerance. Clinical studies that examined the drug's effectiveness over periods of up to 28 days showed no evidence of tolerance to the antihistaminic effect. Second-generation antihistamines like Loratyne are not commonly associated with this effect.

Q: Are there any known interactions between Loratyne and pain relievers?

A: Official regulatory documents do not list common over-the-counter pain relievers, such as ibuprofen or acetaminophen, as restricted or contraindicated interactions. It is important for patients to inform a healthcare professional about all medications, including pain relievers, that are being taken.

Q: Does Loratyne contain any ingredients that could be harmful to people with common food allergies?

A: The different formulations of the drug utilize various ingredients. Importantly, some forms, like the chewable tablet, contain phenylalanine (aspartame), which is specifically warned against for individuals with the metabolic disorder Phenylketonuria (PKU). Patients should review the inactive ingredients for specific sensitivities.

Q: Is there a risk of rebound symptoms if I stop taking Loratyne suddenly?

A: If a drug is stopped suddenly after regular, long-term use, there is a general potential for the body to experience rebound allergy symptoms, which means the original symptoms may temporarily intensify. The concept of rebound allergy symptoms has been noted in the context of stopping some antihistamines after prolonged use.

Q: Is it true that Loratyne is generally considered to have fewer side effects than first-generation antihistamines?

A: Yes, this statement is supported by official classification. Loratyne is designated as a second-generation compound primarily because it is positioned as having significantly fewer central nervous system side effects, such as sedation and cognitive impairment, compared to older first-generation antihistamines.

Q: How is the evidence for Loratyne described in research papers?

A: Research summarized in regulatory documents describes findings that show patterns related to symptom scores when compared to a placebo. Official evidence overviews consistently note that certainty remains low in several domains and that results should be understood to apply only to the populations that were included in the studies.

Q: Why is Loratyne sometimes mentioned as having a 'short half-life' in medical discussions?

A: This reference is specific to the parent drug, Loratadine, which has a half-life of approximately 8.4 text hours. However, the medication's full effect is primarily driven by its major active metabolite, which has a much longer half-life of approximately 28 text hours. It is the combined long-acting profile of the parent drug and its metabolite that enables the once-daily dosing.

Q: Can Loratyne be taken alongside antibiotics?

A: Regulatory documents advise caution when Loratyne is taken alongside antibiotics that are also known as CYP3A4 or CYP2D6 enzyme inhibitors. The antibiotic Erythromycin is specifically cited in official documents as potentially increasing Loratyne plasma concentrations. Patients are advised to review their full medication list with a healthcare provider.

How should Loratyne be stored and disposed of?

How to Store and Dispose of Loratyne (Loratadine)

Official regulatory documentation provides precise mandates for storing and disposing of loratadine to maintain its stability and ensure safety.


Storage Conditions

Loratadine tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture and should not be frozen under any circumstances. Forms such as orally disintegrating tablets (ODT) have stability rules requiring immediate use upon opening the individual blister unit. All containers must be kept out of the reach of children.

Disposal Instructions

Unused or expired loratadine should be discarded safely. The preferred method is through a recognized drug take-back program or collection kiosk. If these are unavailable, the medication must be mixed with an unpalatable substance (like coffee grounds or dirt), sealed in a bag, and placed in household trash. It is strictly prohibited to flush the medicine down a toilet or drain unless explicitly instructed by the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loratyne found in:

A-Z Index: